(Q58125542)

English

Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics

article

In more languages

Statements

scholarly article

0 references

Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics (English)

0 references

amyotrophic lateral sclerosis

0 references

Merit E Cudkowicz

5

object named as

Merit E. Cudkowicz

0 references

author name string

Stacy A. Rudnicki

1

0 references

James D. Berry

2

0 references

Evan Ingersoll

3

0 references

Don Archibald

4

0 references

Douglas A. Kerr

6

0 references

Yingwen Dong

7

0 references

publication date

17 September 2012

0 references

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

0 references

14

0 references

1

0 references

44-51

0 references

Amyotrophic lateral sclerosis mortality in the United States, 1979-2001.

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.723723

21 January 2018

Prognostic factors in ALS: A critical review

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.723723

21 January 2018

Prognosis in amyotrophic lateral sclerosis: a population-based study.

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.723723

21 January 2018

Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.723723

21 January 2018

The ALSFRSr predicts survival time in an ALS clinic population

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.723723

21 January 2018

Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS.

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.723723

21 January 2018

Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.723723

21 January 2018

Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.723723

21 January 2018

Review: The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.723723

21 January 2018

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.723723

21 January 2018

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.723723

21 January 2018

Phase II/III randomized trial of TCH346 in patients with ALS

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.723723

21 January 2018

Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.723723

21 January 2018

Clinical significance in the change of decline in ALSFRS-R

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2012.723723

21 January 2018

Identifiers

10.3109/17482968.2012.723723

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58125542&oldid=1998656285"